Amicus Therapeutics, Inc. (FOLD)
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Investigation
04/13/2022
Initial Lawsuit
05/11/2022
Lawsuit Progression
07/11/2022
This investigation follows the large company’s stock price decline since the initial public offering (IPO). So why the decline? As always, numerous factors impacted the stock since the IPO, but this investors investigation focuses on the following.
As early as one week prior to the completion of the company’s IPO, from March 4, 2021 through March 11, 2021, China held its annual “Two Sessions” parliamentary meetings, where the two main political bodies of China meet, discuss, and reveal plans for China’s policies, including education. The following week, First High-School Education Group conducted its IPO. As of May 16, 2022, the stock price has dropped more than 90%, from the initial $10 IPO price per share.
09/28/2021
The company issues a press release announcing its financial results for the first half of 2021 ended June 30, 2021, disclosing revenue of RMB231.9 million, a year-over-year increase of only 24.8%, compared to 30.5% year-over-year revenue increase for first nine months of 2020, and 32.5% year-over-year revenue increase for the full year 2020. The company explained that rules impacting its business “have set series of restrictions and guidelines on operation, taxation, shareholding structure, connected transactions and merge and acquisition of compulsory education.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$3 | $3.89 | $-0.89 | -22.88% |
This is a securities class action on behalf of all persons or entities who purchased First High-School Education Group Co., Ltd. American depositary shares (ADSs) in or traceable to the company’s March 2021 initial public offering (IPO).
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(a) that the new rules, regulations and policies to be implemented by the Chinese government following its annual “Two Sessions” parliamentary meetings were far more severe than represented to investors and posed a material adverse threat to the company and its business;
(b) that contemplated Chinese regulations and rules regarding private education were leading to a slowdown of government approval to open new educational facilities which would have a negative effect on First High-School Education’s enrollment and growth; and
(c) that, as a result, the registration statement’s representations regarding First High-School Education’s historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the company at the time of the IPO, and were materially false and misleading and lacked a factual basis.
The lead plaintiff deadline has passed, we will update this page as the lawsuit progresses.
Last event retrieved on 09/24/2022.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.